Best Practices in the Management of SCCHN With Checkpoint Inhibition

Access Course

 

Best Practices in the Management of SCCHN With Checkpoint InhibitionDr Dan Zandberg reviews the latest understanding in the use of checkpoint inhibition in SCCHN through an examination of 3 cases.

 

This activity is intended for oncologists, surgeons, and pathologists.

 

The goal of this activity is to increase understanding of the use of checkpoint inhibition in advanced squamous cell carcinoma of the head and neck (SCCHN) as well as ongoing research into its use earlier in the disease setting.

 

Learning Objectives:

  • Have increased knowledge regarding the evidence-based management of patients with SCCHN
  • Have increased knowledge regarding the role of cancer immunotherapy clinical trials
  • Have greater competence related to selecting the most appropriate cancer immunotherapy regimen for patients with SCCHN
  • Have greater competence related to managing immune-related adverse effects

 

Approximate Time to Complete: 1 hour

 

Credit Available: May 9, 2019 - May 9, 2020

 

Developed through a partnership between SITC and Medscape.

sitc_log_color.png      Medscape_EDU-RGB-2x-300.png

 

Additional Resources for Clinicans from SITC:

 

sitc-cig-rgb.png

"The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of squamous cell carcinoma of the head and neck (HNSCC)" (Published July 15, 2019)

 

 

 

View Guidelines Here.

View On-Demand Webinar Here.

Accreditation Council For Continuing Medical Education
AMA PRA Category 1 Credit(s)â„¢: 1.00
American Board of Internal Medicine
ABIM MOC Part 2 Credits: 1.00